1. Home
  2. SILO vs PFSA Comparison

SILO vs PFSA Comparison

Compare SILO & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

N/A

Current Price

$0.34

Market Cap

4.6M

ML Signal

N/A

PFSA

Profusa Inc.

N/A

Current Price

$0.89

Market Cap

3.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SILO
PFSA
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
3.7M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
SILO
PFSA
Price
$0.34
$0.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
425.1K
288.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.83
N/A
EPS
N/A
N/A
Revenue
$72,102.00
N/A
Revenue This Year
$1.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.05
52 Week High
$1.44
$4.22

Technical Indicators

Market Signals
Indicator
SILO
PFSA
Relative Strength Index (RSI) 51.92 44.61
Support Level $0.33 $0.85
Resistance Level $0.45 $2.22
Average True Range (ATR) 0.04 0.19
MACD 0.00 -0.12
Stochastic Oscillator 77.96 3.54

Price Performance

Historical Comparison
SILO
PFSA

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: